TRIS PHARMA INC FDA Approval NDA 208147

NDA 208147

TRIS PHARMA INC

FDA Drug Application

Application #208147

Documents

Label2015-10-22
Review2016-06-30
Summary Review2016-06-30
Letter2015-10-22
Label2017-01-06
Letter2017-01-10
Label2017-05-22
Medication Guide2017-05-22
Pediatric Medical Review1900-01-01
Pediatric Clinical Pharmacology Review1900-01-01
Pediatric Statistical Review1900-01-01
Label2019-02-07
Medication Guide2019-02-07
Letter2019-02-08
Letter2022-02-28
Label2022-03-02
Medication Guide2022-03-02
Letter2022-06-02
Label2022-06-06

Application Sponsors

NDA 208147TRIS PHARMA INC

Marketing Status

Prescription001

Application Products

001SUSPENSION, EXTENDED RELEASE;ORALEQ 2.5MG BASE/ML1DYANAVEL XRAMPHETAMINE

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2015-10-19STANDARD
LABELING; LabelingSUPPL2AP2017-01-04901 REQUIRED
MANUF (CMC); Manufacturing (CMC)SUPPL3AP2017-05-12N/A
EFFICACY; EfficacySUPPL5AP2019-02-05STANDARD
LABELING; LabelingSUPPL12AP2022-06-01STANDARD
LABELING; LabelingSUPPL13AP2022-02-25901 REQUIRED

Submissions Property Types

ORIG1Null7
SUPPL2Null6
SUPPL3Null6
SUPPL5Null15
SUPPL12Null15
SUPPL13Null7

CDER Filings

TRIS PHARMA INC
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 208147
            [companyName] => TRIS PHARMA INC
            [docInserts] => ["Medication Guide",""]
            [products] => [{"drugName":"DYANAVEL XR","activeIngredients":"AMPHETAMINE","strength":"EQ 2.5MG BASE\/ML","dosageForm":"SUSPENSION, EXTENDED RELEASE;ORAL","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"}]
            [labels] => [{"actionDate":"02\/05\/2019","submission":"SUPPL-5","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/208147s005lbl.pdf\"}]","notes":""},{"actionDate":"05\/12\/2017","submission":"SUPPL-3","supplementCategories":"Labeling-Medication Guide","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/208147s003lbl.pdf\"}]","notes":""},{"actionDate":"01\/04\/2017","submission":"SUPPL-2","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/208147s002lbl.pdf\"}]","notes":""},{"actionDate":"10\/19\/2015","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/208147s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"10\/19\/2015","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/208147s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2015\\\/208147Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2015\\\/208147Orig1DyanavelTOC.cfm\"},{\"name\":\"Summary Review (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2015\\\/208147Orig1s000SumR_6pgs_rev1rev2kc_Redacted.pdf\"}]","notes":">"}]
            [supplements] => [{"actionDate":"02\/05\/2019","submission":"SUPPL-5","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/208147s005lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2019\\\/208147Orig1s005ltr.pdf\"}]","notes":">"},{"actionDate":"05\/12\/2017","submission":"SUPPL-3","supplementCategories":"Labeling-Medication Guide","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/208147s003lbl.pdf\"}]","notes":">"},{"actionDate":"01\/04\/2017","submission":"SUPPL-2","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/208147s002lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2017\\\/208147Orig1s002ltr.pdf\"}]","notes":">"}]
            [actionDate] => 2019-02-05
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.